Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander van Deventer

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Immunotherapy|November 25, 2010
Regulatory T cells as potential targets for immunotherapy in inflammatory bowel diseaseCaterina Strisciuglio, Sander van Deventer
Gut|January 12, 2021
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the futureGeert R D'Haens, Sander van Deventer
Nature Biotechnology|April 15, 2014
Acquiring orphansRogier Rooswinkel, Geert-Jan Mulder, Sander van Deventer
Nature Biotechnology|April 9, 2013
Building for big pharmaAsiya Giniatullina, Marco Boorsma, Geert-Jan Mulder, et al.
Nature Biotechnology|February 16, 2021
How large pharma impacts biotechnology startup successGina Melchner von Dydiowa, Sander van Deventer, Daniela S Couto
Journal of Crohn'S & Colitis|April 3, 2012
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapySimon Travis, Brian G Feagan, Paul Rutgeerts, et al.
Biochemical Pharmacology|September 6, 2002
Inflammatory signal transduction in Crohn's disease and novel therapeutic approachesCatherine van Montfrans, Maikel Peppelenbosch, Anje A te Velde, et al.
Frontiers in Neuroscience|July 23, 2025
Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab<sup>®</sup>Andreia Gomes-Duarte, Sofia Pascoal, Rob Haselberg, et al.
Nature Biotechnology|April 4, 2019
Mapping the European startup landscapeBonnie van Wilgenburg, Kim van Wilgenburg, Kathryn Paisner, et al.
BMC Biotechnology|July 26, 2012
Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100Piotr Maczuga, Annemart Koornneef, Florie Borel, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Immunotherapy|November 25, 2010
Regulatory T cells as potential targets for immunotherapy in inflammatory bowel diseaseCaterina Strisciuglio, Sander van Deventer
Gut|January 12, 2021
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the futureGeert R D'Haens, Sander van Deventer
Nature Biotechnology|April 15, 2014
Acquiring orphansRogier Rooswinkel, Geert-Jan Mulder, Sander van Deventer
Nature Biotechnology|April 9, 2013
Building for big pharmaAsiya Giniatullina, Marco Boorsma, Geert-Jan Mulder, et al.
Nature Biotechnology|February 16, 2021
How large pharma impacts biotechnology startup successGina Melchner von Dydiowa, Sander van Deventer, Daniela S Couto
Journal of Crohn'S & Colitis|April 3, 2012
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapySimon Travis, Brian G Feagan, Paul Rutgeerts, et al.
Biochemical Pharmacology|September 6, 2002
Inflammatory signal transduction in Crohn's disease and novel therapeutic approachesCatherine van Montfrans, Maikel Peppelenbosch, Anje A te Velde, et al.
Frontiers in Neuroscience|July 23, 2025
Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab<sup>®</sup>Andreia Gomes-Duarte, Sofia Pascoal, Rob Haselberg, et al.
Nature Biotechnology|April 4, 2019
Mapping the European startup landscapeBonnie van Wilgenburg, Kim van Wilgenburg, Kathryn Paisner, et al.
BMC Biotechnology|July 26, 2012
Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100Piotr Maczuga, Annemart Koornneef, Florie Borel, et al.
Pageof 4